2025
Chemically Induced Hypertension: Antineoplastic Agents Associated with High Blood Pressure
Moss E, Shirali A. Chemically Induced Hypertension: Antineoplastic Agents Associated with High Blood Pressure. Updates In Hypertension And Cardiovascular Protection 2025, 79-91. DOI: 10.1007/978-3-031-81292-7_5.Peer-Reviewed Original ResearchVascular endothelial growth factor signal pathway inhibitorsAdverse effects of anticancer therapyEffects of anticancer therapySystemic adverse effectsTyrosine kinase inhibitorsExacerbation of hypertensionTreatment of malignanciesDevelopment of hypertensionAssociated with hypertensionDrug-drug interactionsBlood pressure monitoringSignaling pathway inhibitorsCalcineurin inhibitorsHigh blood pressureAdjuvant medicationsAntineoplastic therapyProteosome inhibitorKinase inhibitorsIncreased riskSubsequent treatmentAnticancer therapyPathway inhibitorBlood pressureAntineoplastic drugsHypertension
2022
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study
Harrington KJ, Burtness B, Greil R, Soulières D, Tahara M, de Castro G, Psyrri A, Brana I, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesia R, Ngamphaiboon N, Rordorf T, Ishak W, Lin J, Gumuscu B, Swaby RF, Rischin D. Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. Journal Of Clinical Oncology 2022, 41: 790-802. PMID: 36219809, PMCID: PMC9902012, DOI: 10.1200/jco.21.02508.Peer-Reviewed Original ResearchConceptsPD-L1 CPSNeck squamous cell carcinomaSquamous cell carcinomaRecurrent/metastatic headMetastatic headCell carcinomaOverall survivalNext-line therapyObjective response ratePembrolizumab-based therapyProgression-free survivalDeath ligand 1Long-term efficacyKEYNOTE-048Data cutoffSurvival benefitTotal populationMedian studyPembrolizumabResponse rateCarcinomaPositive scoreLigand 1Subsequent treatmentEfficacyNon-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, DeCamp M, Dilling TJ, Dowell J, Gettinger S, Grotz TE, Gubens MA, Hegde A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Ng T, Otterson GA, Pacheco JM, Patel SP, Riely GJ, Riess J, Schild SE, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory K, Hughes M. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2022, 20: 497-530. PMID: 35545176, DOI: 10.6004/jnccn.2022.0025.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerNCCN Clinical Practice GuidelinesCell lung cancerClinical practice guidelinesLung cancerPractice guidelinesMetastatic non-small cell lung cancerMetastatic lung cancerNCCN guidelinesPrimary treatmentTargeted therapyActionable mutationsPatientsCancerSubsequent treatmentTherapyOncologyTreatmentGuidelinesImmunotherapyRelapseDiagnosis
2020
Low-Density Lipoprotein-Cholesterol Lowering in Patients with a Recent Myocardial Infarction and Subsequent Treatment with Evolocumab in Real-World Clinical Practice
Desai N, Xiang P, Exter J, Habib M, Wang X, Nunna S, Wade R, Mues K, Chen C. Low-Density Lipoprotein-Cholesterol Lowering in Patients with a Recent Myocardial Infarction and Subsequent Treatment with Evolocumab in Real-World Clinical Practice. Journal Of Clinical Lipidology 2020, 14: 551-552. DOI: 10.1016/j.jacl.2020.05.018.Peer-Reviewed Original ResearchEstrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival
Sperduto PW, Mesko S, Li J, Cagney D, Aizer A, Lin NU, Nesbit E, Kruser TJ, Chan J, Braunstein S, Lee J, Kirkpatrick JP, Breen W, Brown PD, Shi D, Shih HA, Soliman H, Sahgal A, Shanley R, Sperduto W, Lou E, Everett A, Boggs DH, Masucci L, Roberge D, Remick J, Plichta K, Buatti JM, Jain S, Gaspar LE, Wu CC, Wang TJC, Bryant J, Chuong M, Yu J, Chiang V, Nakano T, Aoyama H, Mehta MP. Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival. Neuro-Oncology 2020, 22: 1359-1367. PMID: 32034917, PMCID: PMC7523450, DOI: 10.1093/neuonc/noaa025.Peer-Reviewed Original ResearchConceptsBreast cancer brain metastasesHuman epidermal growth factor receptor 2Primary tumorProgesterone receptorMedian survivalEstrogen receptorBrain metastasesDiscordance rateHER2-negative primary tumorsEstrogen/progesterone receptorsEpidermal growth factor receptor 2Time of metastasisCancer brain metastasesGrowth factor receptor 2Breast cancer treatmentIncidence of discordanceFactor receptor 2Subsequent treatmentBCBM patientsHER2 discordanceReceptor discordanceMost patientsReceptor statusInitial diagnosisHER2 status
2019
Chapter 83 Adaptive Immunity and Critical Illness
Schulte W, Maerz L, Moeckel G, Bucala R. Chapter 83 Adaptive Immunity and Critical Illness. 2019, 483-487. DOI: 10.1016/b978-0-323-44942-7.00083-2.Peer-Reviewed Original ResearchAcute kidney injuryCritical illnessEnd-stage renal diseaseChronic kidney diseaseChallenging clinical conditionIschemia-reperfusion injuryComplex disease processAdaptive immune systemAKI pathophysiologyKidney injuryHospitalized patientsRenal diseaseKidney diseaseInflammatory processCommon causeClinical conditionsAdaptive immunityLong-term consequencesDisease processImmune systemSubsequent treatmentInjuryIllnessDiseaseCurrent knowledge
2018
RET rearrangements are actionable alterations in breast cancer
Paratala BS, Chung JH, Williams CB, Yilmazel B, Petrosky W, Williams K, Schrock AB, Gay LM, Lee E, Dolfi SC, Pham K, Lin S, Yao M, Kulkarni A, DiClemente F, Liu C, Rodriguez-Rodriguez L, Ganesan S, Ross JS, Ali SM, Leyland-Jones B, Hirshfield KM. RET rearrangements are actionable alterations in breast cancer. Nature Communications 2018, 9: 4821. PMID: 30446652, PMCID: PMC6240119, DOI: 10.1038/s41467-018-07341-4.Peer-Reviewed Original ResearchMeSH KeywordsAnilidesAnimalsAntineoplastic AgentsBreast NeoplasmsCell Line, TumorCell Transformation, NeoplasticFemaleGene Expression Regulation, NeoplasticHumansMCF-7 CellsMiceMice, NudeMitogen-Activated Protein KinasesNIH 3T3 CellsNuclear Receptor CoactivatorsOncogene Proteins, FusionPhosphatidylinositol 3-KinasesPiperidinesProto-Oncogene Proteins c-retPyridinesQuinazolinesras Guanine Nucleotide Exchange FactorsReceptor, ErbB-2Signal TransductionXenograft Model Antitumor AssaysConceptsBreast cancerRET amplificationRET gene alterationsMetastatic breast cancerNCOA4-RET fusionXenograft tumor formationPI3K pathwayRadiographic responseActionable alterationsLung cancerRET fusionsRET alterationsRET inhibitionIndex caseTherapeutic targetRET rearrangementsCancerGenomic profilingGene alterationsK pathwayTumor formationGene RETNon-tumorigenic cellsSubsequent treatmentOncogenic potential
2016
Bilateral atypical femur fractures without bisphosphonate exposure
Szolomayer LK, Ibe IK, Lindskog DM. Bilateral atypical femur fractures without bisphosphonate exposure. Skeletal Radiology 2016, 46: 241-247. PMID: 27900455, DOI: 10.1007/s00256-016-2526-0.Peer-Reviewed Original ResearchConceptsAtypical femur fracturesSubtrochanteric femur fracturesFemur fracturesCommon radiographic featuresLateral cortical thicknessBisphosphonate exposureBisphosphonate medicationBisphosphonate useProphylactic treatmentRadiographic featuresMedical historyFemoral cortexAtypical featuresCortical thicknessFracture typeContralateral femurSubsequent treatmentTransverse fracturesMedicationsPatientsOnly causeFracturesTreatmentInjuryCortexA lupus anti-DNA autoantibody mediates autocatalytic, targeted delivery of nanoparticles to tumors
Chen Z, Patel JM, Noble PW, Garcia C, Hong Z, Hansen JE, Zhou J. A lupus anti-DNA autoantibody mediates autocatalytic, targeted delivery of nanoparticles to tumors. Oncotarget 2016, 7: 59965-59975. PMID: 27494868, PMCID: PMC5312362, DOI: 10.18632/oncotarget.11015.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, AntinuclearAntibodies, CatalyticBreast NeoplasmsCell Line, TumorDNADoxorubicinDrug Delivery SystemsFemaleHumansLactic AcidLupus Coagulation InhibitorMammary Neoplasms, AnimalMiceMice, Inbred BALB CNanoparticlesPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerTumor MicroenvironmentConceptsDelivery of nanoparticlesDOX-loaded nanoparticlesTumor-targeting mechanismDrug delivery mechanismsAmount of moleculesNanoparticle deliveryLupus anti-DNA autoantibodiesNanoparticlesProof of conceptRelease of DNASurface modificationBind moleculesAutocatalytic effectDelivery mechanismTumor neovasculatureMoleculesDeliveryDoxorubicinTumor microenviromentMajor limitationEfficiencyLigandsSubsequent treatmentToxic agentsDNA
2009
Plasmapheresis therapy for rare but potentially fatal reaction to rituximab
Hastings D, Patel B, Torloni AS, Mookadam F, Betcher J, Moss A, Heilman R, Mazur M, Hamawi K, Mulligan D, Reddy K, Mekeel K, Chakkera H. Plasmapheresis therapy for rare but potentially fatal reaction to rituximab. Journal Of Clinical Apheresis 2009, 24: 28-31. PMID: 19156754, DOI: 10.1002/jca.20187.Peer-Reviewed Original ResearchConceptsPlasmapheresis therapyFatal reactionsClinical conditionsHigh-dose vasopressorsHospital day 5Human IgG1 monoclonal antibodyNear-fatal reactionsPatient's clinical conditionIgG1 monoclonal antibodyRituximab therapyInfusion reactionsSupportive careRespiratory compromiseMedical managementCD20 antigenSpecific treatmentDisease processDay 5RituximabMonoclonal antibodiesTherapyMedical communitySubsequent treatmentPlasmapheresisNumerous diseasesDepressive Symptoms, Drinking Consequences, and Motivation to Change in First Time DWI Offenders
Holt LJ, O'Malley SS, Rounsaville BJ, Ball SA. Depressive Symptoms, Drinking Consequences, and Motivation to Change in First Time DWI Offenders. The American Journal Of Drug And Alcohol Abuse 2009, 35: 117-122. PMID: 19462293, PMCID: PMC3679647, DOI: 10.1080/00952990802585398.Peer-Reviewed Original ResearchConceptsBeck Depression InventoryDepressive symptomsFirst-time DWI offendersPretreatment depressive symptomsUseful screening toolHigh-risk drinkingPsychosocial assessmentSevere symptomatologyDrinking consequencesAlcohol consumptionDepression InventorySymptomsDWI arrestsScreening toolTime pointsDWI offendersIntervention outcomesDrinking-related consequencesSubsequent treatmentDrinking behaviorPsychological disordersInterventionArrestDrinkingCurrent study
2005
SCL-90 symptom patterns: indicators of dissociative disorders.
Steinberg M, Barry DT, Sholomskas D, Hall P. SCL-90 symptom patterns: indicators of dissociative disorders. Bulletin Of The Menninger Clinic 2005, 69: 237-49. PMID: 16178712, DOI: 10.1521/bumc.2005.69.3.237.Peer-Reviewed Original ResearchConceptsGlobal Severity IndexDissociative disordersDSM-IV Dissociative DisordersSCL-90 profilesSCL-90 Global Severity IndexStructured Clinical InterviewSymptom Checklist-90Dissociative identity disorderSymptom assessmentAdult outpatientsDifferential diagnosisIndividual subscale scoresClinical InterviewSCL-90Severity IndexSubscale scoresDisordersSubsequent treatmentPatientsIdentity disorderOutpatientsDiagnosis
1998
Naltrexone Augmentation of Neuroleptics in Schizophrenia
Sernyak M, Glazer W, Heninger G, Charney D, Woods S, Petrakis I, Krystal J, Price L. Naltrexone Augmentation of Neuroleptics in Schizophrenia. Journal Of Clinical Psychopharmacology 1998, 18: 248-251.. PMID: 9617985, DOI: 10.1097/00004714-199806000-00011.Peer-Reviewed Original ResearchConceptsBrief Psychiatric Rating ScaleTotal BPRS scoreBPRS scoresNegative symptomsAddition of naltrexoneBPRS subscale scoresOngoing neuroleptic treatmentSingle-blind basisPlacebo-controlled trialSingle-blind fashionSubscale scoresBPRS total scorePsychiatric Rating ScaleDSM-III criteriaSubsequent treatmentRepeated-measures analysisNaltrexone augmentationNeuroleptic medicinesNeuroleptic regimenTransient exacerbationPlacebo armNeuroleptic treatmentClinical benefitRepeated-measures ANOVANaltrexone
1997
Bone marrow transplant nephropathy: a case report and review of the literature.
Cruz D, Perazella M, Mahnensmith R. Bone marrow transplant nephropathy: a case report and review of the literature. Journal Of The American Society Of Nephrology 1997, 8: 166-73. PMID: 9013462, DOI: 10.1681/asn.v81166.Peer-Reviewed Original ResearchConceptsBone marrow transplant nephropathyBone marrow transplantationRenal injuryTransplant nephropathyMarrow transplantationLate renal injuryEarly renal injuryHemolytic uremic syndromeVariety of causesNephrotoxic medicationsRenal failurePathologic featuresCase reportUremic syndromeLate effectsRadiation therapyRenal syndromeSyndromeNephropathySubsequent treatmentTransplantationInjuryMedicationsChemotherapyReview
1996
A Putative Poststreptococcal Case of OCD with Chronic Tic Disorder, Not Otherwise Specified
TUCKER D, LECKMAN J, SCAHILL L, WILF G, LaCAMERA R, CARDONA L, COHEN P, HEIDMANN S, GOLDSTEIN J, JUDGE J, SNYDER E, BULT A, PETERSON B, KING R, LOMBROSO P. A Putative Poststreptococcal Case of OCD with Chronic Tic Disorder, Not Otherwise Specified. Journal Of The American Academy Of Child & Adolescent Psychiatry 1996, 35: 1684-1691. PMID: 8973076, DOI: 10.1097/00004583-199612000-00022.Peer-Reviewed Original ResearchConceptsChronic tic disorderTic disordersSelective serotonin reuptake inhibitorsSessions of plasmapheresisSerotonin reuptake inhibitorsUpper respiratory symptomsTreatment-resistant casesClinical laboratory dataCognitive behavioral therapyNeuroimmunological perspectiveProphylactic penicillinRespiratory symptomsReuptake inhibitorsObsessive-compulsive disorderConventional pharmacotherapyTreatment optionsSupportive psychotherapyFamily interventionsSeparation anxietyLaboratory dataSubsequent treatmentDisordersPsychotherapyMultiple perspectivesPharmacotherapyWhy the Urgency for Earlier Diagnosis of HIV Infection in Women?
Parsey K, Livingston E, Butterfield M, Bastian L. Why the Urgency for Earlier Diagnosis of HIV Infection in Women? Medscape Journal Of Medicine 1996, 1: 2. PMID: 9746635.Peer-Reviewed Original ResearchHIV infectionEarly diagnosisVertical transmissionIntravenous drug abusersShorter median survivalReluctance of cliniciansPublic health standpointPregnant patientsProphylactic therapyMedian survivalFemale patientsWorse prognosisLate presentationPregnant womenTubal ligationHeterosexual contactDisease progressionHomosexual menDrug abusersEarly identificationInfectionHealth standpointWomenDiagnosisSubsequent treatment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply